Post-earnings recap
Reported
Thu, May 2, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Kiniksa Pharmaceuticals reported a loss per share of $1.27 but did not provide revenue figures or future guidance. The stock reacted positively, rising 1.89%, possibly due to investor optimism about the company's ongoing clinical trials and product development efforts despite the lack of specific financial metrics.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.27 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management emphasized the importance of their clinical pipeline. There was no specific guidance provided for future performance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on ongoing clinical trials and product development.